Research programme: inflammation therapeutics - Vernalis

Drug Profile

Research programme: inflammation therapeutics - Vernalis

Latest Information Update: 01 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono; Vernalis
  • Developer Vernalis
  • Class
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 01 Aug 2011 Preclinical trials in Inflammation in United Kingdom (unspecified route)
  • 16 Aug 2010 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 22 Oct 2008 Vernalis regains all rights to anti-inflammatory compounds identified through a license, development and commercialisation agreement with Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top